Originally published as JCO Early Release 10.1200/JCO.2005.04.3224 on February 27 2006

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pham, D. Articles by Rusch, V. W. Search for Related Content PubMed PubMed Citation Articles by Pham, D. Articles by Rusch, V. W. Social Bookmarking                            What's this?

Use of Cigarette-Smoking History to Estimate the Likelihood of Mutations in Epidermal Growth Factor Receptor Gene Exons 19 and 21 in Lung Adenocarcinomas

DuyKhanh Pham, Mark G. Kris, Gregory J. Riely, Inderpal S. Sarkaria, Tiffani McDonough, Shaokun Chuai, Ennapadam S. Venkatraman, Vincent A. Miller, Marc Ladanyi, William Pao, Richard K. Wilson, Bhuvanesh Singh, Valerie W. Rusch

From the Departments of Surgery, Medicine, Epidemiology and Biostatistics, and Pathology, Memorial Sloan-Kettering Cancer Center; Weill Medical College of Cornell University, New York, NY; and the Genome Sequencing Center, Washington University, St Louis, MO.

Address reprint requests to Mark G. Kris, MD, Memorial Hospital, 1275 York Avenue, New York, NY 10021

PURPOSE: Lung adenocarcinomas with mutations in exons 19 and 21 of the epidermal growth factor receptor gene (EGFR) demonstrate sensitivity to gefitinib or erlotinib. Investigators have reported an association between EGFR mutations and the amount and duration of cigarette smoking, with the highest incidence of mutations seen in never smokers.

METHODS: EGFR exon 19 and 21 mutation status was determined in 265 tumor samples using direct sequencing, polymerase chain reaction (PCR), or PCR-based restriction fragment length polymorphism analysis. A detailed smoking history was obtained. Patients were categorized as never smokers (< 100 lifetime cigarettes), former smokers (quit 1 year ago), or current smokers (quit < 1 year ago).

RESULTS: We detected EGFR mutations in 34 (51%) of 67 never smokers (95% CI, 38% to 64%), 29 (19%) of 151 former smokers (95% CI, 13% to 27%), and two (4%) of 47 current smokers (95% CI, 1% to 16%). Significantly fewer EGFR mutations were found in people who smoked for more than 15 pack-years (P < .001) or stopped smoking less than 25 years ago (P < .02) compared with individuals who never smoked. The number of smoking pack-years and smoke-free years predicted the prevalence of EGFR mutations (areas under receiver operating characteristic curve = 0.78 and 0.77, respectively).

CONCLUSION: The likelihood of EGFR mutations in exons 19 and 21 decreases as the number of pack-years increases. Mutations were less common in people who smoked for more than 15 pack-years or who stopped smoking cigarettes less than 25 years ago. These data can assist clinicians in assessing the likelihood of exon 19 and 21 EGFR mutations in patients with lung adenocarcinoma when mutational analysis is not feasible.

Supported in part by Genentech Inc, the Steps for Breath Lung Cancer Research Program of the Society of Memorial Sloan-Kettering, and the Carmel Hill Fund.

Presented in part at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005.

Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. Schmid, N. Oehl, F. Wrba, R. Pirker, C. Pirker, and M. Filipits EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases Clin. Cancer Res., July 15, 2009; 15(14): 4554 - 4560. [Abstract] [Full Text] [PDF]

				R. A. Mason, E. V. Morlock, M. R. Karagas, K. T. Kelsey, C. J. Marsit, A. R. Schned, and A. S. Andrew EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis Carcinogenesis, July 1, 2009; 30(7): 1155 - 1160. [Abstract] [Full Text] [PDF]

				M. PESEK, L. BENESOVA, B. BELSANOVA, P. MUKENSNABL, F. BRUHA, and M. MINARIK Dominance of EGFR and Insignificant KRAS Mutations in Prediction of Tyrosine-kinase Therapy for NSCLC Patients Stratified by Tumor Subtype and Smoking Status Anticancer Res, July 1, 2009; 29(7): 2767 - 2773. [Abstract] [Full Text] [PDF]

				G. J. Riely, J. Marks, and W. Pao KRAS Mutations in Non-Small Cell Lung Cancer Proceedings of the ATS, April 15, 2009; 6(2): 201 - 205. [Abstract] [Full Text] [PDF]

				T. E. Stinchcombe and M. A. Socinski Current Treatments for Advanced Stage Non-Small Cell Lung Cancer Proceedings of the ATS, April 15, 2009; 6(2): 233 - 241. [Abstract] [Full Text] [PDF]

				M. M. Schittenhelm, C. Kollmannsberger, K. Oechsle, A. Harlow, J. Morich, F. Honecker, R. Kurek, S. Storkel, L. Kanz, C. L. Corless, et al. Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer Mol. Cancer Ther., March 1, 2009; 8(3): 481 - 489. [Abstract] [Full Text] [PDF]

				G. J. Riely, M. G. Kris, D. Rosenbaum, J. Marks, A. Li, D. A. Chitale, K. Nafa, E. R. Riedel, M. Hsu, W. Pao, et al. Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma Clin. Cancer Res., September 15, 2008; 14(18): 5731 - 5734. [Abstract] [Full Text] [PDF]

				L. V. Sequist, J. E. Settleman, J. B. Ackman, and A. J. Iafrate Case 23-2008 -- A 26-Year-Old Man with Back Pain and a Mass in the Lung N. Engl. J. Med., July 24, 2008; 359(4): 405 - 414. [Full Text] [PDF]

				J. P. Koivunen, C. Mermel, K. Zejnullahu, C. Murphy, E. Lifshits, A. J. Holmes, H. G. Choi, J. Kim, D. Chiang, R. Thomas, et al. EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer Clin. Cancer Res., July 1, 2008; 14(13): 4275 - 4283. [Abstract] [Full Text] [PDF]

				L. V. Sequist, R. G. Martins, D. Spigel, S. M. Grunberg, A. Spira, P. A. Janne, V. A. Joshi, D. McCollum, T. L. Evans, A. Muzikansky, et al. First-Line Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Somatic EGFR Mutations J. Clin. Oncol., May 20, 2008; 26(15): 2442 - 2449. [Abstract] [Full Text] [PDF]

				V. A. Miller, G. J. Riely, M. F. Zakowski, A. R. Li, J. D. Patel, R. T. Heelan, M. G. Kris, A. B. Sandler, D. P. Carbone, A. Tsao, et al. Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib J. Clin. Oncol., March 20, 2008; 26(9): 1472 - 1478. [Abstract] [Full Text] [PDF]

				F. Ciardiello and G. Tortora EGFR Antagonists in Cancer Treatment N. Engl. J. Med., March 13, 2008; 358(11): 1160 - 1174. [Full Text] [PDF]

				M. V. Karamouzis, J. R. Grandis, and A. Argiris Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas JAMA, July 4, 2007; 298(1): 70 - 82. [Abstract] [Full Text] [PDF]

				H.-J. Haussmann Smoking and Lung Cancer: Future Research Directions International Journal of Toxicology, July 1, 2007; 26(4): 353 - 364. [Abstract] [Full Text] [PDF]

				F. Cappuzzo, C. Ligorio, P. A. Janne, L. Toschi, E. Rossi, R. Trisolini, D. Paioli, A. J. Holmes, E. Magrini, G. Finocchiaro, et al. Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization-Positive/Phospho-Akt-Positive or Never Smoker Patients With Advanced Non-Small-Cell Lung Cancer: The ONCOBELL Trial J. Clin. Oncol., June 1, 2007; 25(16): 2248 - 2255. [Abstract] [Full Text] [PDF]

				T. Li, Y.-H. Ling, I. D. Goldman, and R. Perez-Soler Schedule-Dependent Cytotoxic Synergism of Pemetrexed and Erlotinib in Human Non-Small Cell Lung Cancer Cells Clin. Cancer Res., June 1, 2007; 13(11): 3413 - 3422. [Abstract] [Full Text] [PDF]

				H. A. Wakelee, E. T. Chang, S. L. Gomez, T. H. Keegan, D. Feskanich, C. A. Clarke, L. Holmberg, L. C. Yong, L. N. Kolonel, M. K. Gould, et al. Lung Cancer Incidence in Never Smokers J. Clin. Oncol., February 10, 2007; 25(5): 472 - 478. [Abstract] [Full Text] [PDF]

				L. Toschi and F. Cappuzzo Understanding the New Genetics of Responsiveness to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Oncologist, February 1, 2007; 12(2): 211 - 220. [Abstract] [Full Text] [PDF]

				L. V. Sequist, V. A. Joshi, P. A. Janne, A. Muzikansky, P. Fidias, M. Meyerson, D. A. Haber, R. Kucherlapati, B. E. Johnson, and T. J. Lynch Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist, January 1, 2007; 12(1): 90 - 98. [Abstract] [Full Text] [PDF]